A third abscopal response is monumental news, in my opinion. It does not guarantee that DARRT-1 will deliver abscopal responses in every patient, but it improves the odds that DARRT results will be good.
Data should be published by early August. It will include 6-week responses for the 400 mg, 800 mg and 1200 mg cohorts; 12-week response for the 400 mg group; and probably the 12-week response for the 800 mg group. The 12-week data will give the best indication of efficacy.
In just six or seven weeks we will know whether DARRT-type treatment has the potential to deliver quick, safe and effective therapy. For the sake of cancer patients, I certainly hope so!
A third abscopal response is monumental news, in my opinion. It...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 46575 | 3 |
View Market Depth
| Last trade - 11.05am 27/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable
